p.p1 {margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px} p.p2 {margin: 0.0px 0.0px 0.0px 0.0px; text-align: justify; line-height: 12.1px; font: 9.0px Helvetica; color: #00628f} p.p3 {margin: 0.0px 0.0px 0.0px 0.0px; text-align: justify; line-height: 9.1px; font: 9.0px Helvetica; color: #686a6c} span.s1 {font: 12.0px Helvetica; color: #000000}

The Situation:
Demand for Daiichi Sankyo Inc.’s (DSI) innovative Welchol product – designed to help treat high cholesterol – grew steadily after its launch. However, the drug was only available in rather large tablet dose form and, to work effectively, required the consumption of six tablets daily. As a result, DSI decided not only to increase its production of Welchol, but also to make it available in a powder-based solution. This would make the product available to a broader age range – namely, young children and adults who may have difficulty swallowing pills.